Organisation paid for research Program year 2025 Source: CMS Open Payments

Grayline Research Center

Neither a doctor nor a teaching hospital

Research payments

$339,334

74 payments

Through program year 2025, Grayline Research Center is reported as receiving $339,334 in research payments, across 74 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$123,861	28
2024	Research	$72,524	6
2023	Research	$24,748	4
2022	Research	$5,996	4
2021	Research	$9,828	12
2020	Research	$29,535	13
2019	Research	$72,842	7

Breakdown

Who paid Research payments · program years 2019–2025

Axsome Therapeutics, Inc. $118,744 12 payments
ACADIA Pharmaceuticals Inc $100,633 18 payments
Sage Therapeutics, Inc. $53,234 2 payments
Boehringer Ingelheim International GmbH $25,422 25 payments
AbbVie, Inc. $22,738 3 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $13,501 6 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $5,027 7 payments
Merck Sharp & Dohme Corporation $35 1 payment

Studies the money was for Research payments · program years 2019–2025

A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms $118,744 12 payments
Acp-103-059 $67,842 8 payments
A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder $53,234 2 payments
Acp-103-055 $32,791 10 payments
Phase II DRF study of NR2B modulation in MDD $23,244 10 payments
M23-894 ABBV-932 Ph 2 BPD $16,890 1 payment
PoCC study in patients with PTSD $9,876 9 payments
Proof of concept and DRF in BPD $9,261 11 payments
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects with Generalized Anxiety Disorder who have had an Inadequate Response to Antidepressant Therapies $3,446 1 payment
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder $2,403 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.